2-Deoxy-D-glucose functionalized zinc oxide nanodrug for kidney cancer treatment

Abstract

For the first time, zinc oxide (ZnO) nanoparticles (NPs) are synthesized by the green combustion method using apple peel extract as a reducing agent. Further, ZnO-Deoxy-D-Glucose (2DG) nanohybrids were synthesized by the sputtering method. These synthesized biomolecule-coated NPs and nanohybrids are characterized with different techniques. The Bragg reflections confirm the hexagonal Wurtzite structure for ZnO. A decrease in crystallite size and an increase in energy band gap were observed for ZnO and ZnO-2DG. The tuning of the band gap plays a vital role in cytotoxicity, arbitrated by intracellular reactive oxygen species. The cytotoxic properties, such as the percentage of inhibition and the percentage of the proliferation of ZnO and ZnO-2DG nanohybrid, are examined against the Kidney cancer Vero cell line and also compared with the standard drugs Levofloxacin and Doxorubicin. Compared to ZnO, ZnO-2DG shows excellent cytotoxic properties, even better than the standard drug against the Vero cell line. Thus, the present ZnO-2DG nanohybrid might be used as a nanodrug and go on to replace Levofloxacin and Doxorubicin as standard drugs in kidney cancer cell therapy.